Glecaprevir/Pibrentasvir Real-world Study in China

The Efficacy, Safety and Long-term Prognosis of Glecaprevir/Pibrentasvir in the Treatment of Chronic Hepatitis C Patients in China--A Real-world Study

To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

This study is a multi-center, prospective, real-world study, aiming to investigate the use of Glecaprevir/Pibrentasvir in routine clinical management of chronic hepatitis C patients and evaluate its effectiveness and safety across a heterogeneous population in China.Approximately 800 patients will take part in this study, 20 sites will be included which distribute in China's major cities, thus each site will enroll 40 patients.

Inclusion Criteria:

• >18 years old
• Meet the standard of Glecaprevir/Pibrentasvir treatment

Exclusion Criteria:

• Patients have contraindications to Glecaprevir/Pibrentasvir
• Pregnancy or lactation
• Malignancy
• Decompensatory cirrhosis